ilginatinib

Home
Ligands
ilginatinib

Ligand id: 7839

Name: ilginatinib

Structure and Physico-chemical Properties

2D Structure

Calculated Physico-chemical Properties
Hydrogen bond acceptors	6
Hydrogen bond donors	2
Rotatable bonds	6
Topological polar surface area	80.55
Molecular weight	389.18
XLogP	4.14
No. Lipinski's rules broken	0

Molecular properties generated using the CDK

Summary
Biological activity
Clinical data
References
Structure
Similar ligands

No information available.

No information available.

Summary of Clinical Use
A Phase 1/2 clinical trial to assess the safety and tolerability of oral NS-018 in patients with primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF (NCT01423851) is ongoing but no longer recruiting participants (Aug 2018). Results from the Phase 1 portion of the trial were published in 2017 by Verstovsek et al. [3]. Significant reduction in palpable spleen size and improvements in myelofibrosis-associated symptoms were observed.

Summary of Clinical Use

A Phase 1/2 clinical trial to assess the safety and tolerability of oral NS-018 in patients with primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF (NCT01423851) is ongoing but no longer recruiting participants (Aug 2018). Results from the Phase 1 portion of the trial were published in 2017 by Verstovsek et al. [3]. Significant reduction in palpable spleen size and improvements in myelofibrosis-associated symptoms were observed.